Fly News Breaks for September 3, 2019
Sep 3, 2019 | 10:49 EDT
H.C. Wainwright analyst Douglas Tsao maiontained a Buy rating and $3.50 price target on Trevena. The analyst noted that Trevena recently announced that it completed enrollment for its ongoing healthy volunteer QT study and remained on track to support topline data readout in Q4. Trevena also said that more than 20 of 30 subjects at that point had received the maximum daily dose of 27mg of oliceridine, a key FDA requirement for the trial. This gives Tsao "confidence that the trial should be successful."
News For TRVN From the Last 2 Days
There are no results for your query TRVN